UroGen Pharma - URGN Operating profit EBITDA
UroGen Pharma Ltd. (URGN) focuses on developing unique therapies for urological oncology in the US. The use of proprietary slow-release gels ensures high sales margins. Meanwhile, the humanitarian status of the drugs minimizes the impact of global trade disputes. The absolute EBITDA trend demonstrates the business's real cash flow, where the 0.00 metric determines this level.
Summary analytical data breakdowns for UroGen Pharma (URGN)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
URGN - Company Net Income|Net Profit Forecast UroGen Pharma Ltd.|URGN - Price to Earnings Ratio|Future Price to Earnings Multiple urogen.com|URGN - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio UroGen Pharma|URGN - Operating profit EBITDA|Earnings per share for the trailing year UroGen Pharma|URGN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth urogen.com|URGN - Earnings per share growth in current year|Expected earnings per share trend next year UroGen Pharma Ltd.
- sales revenue and business income indicators:
Analysis of all company metrics:UroGen Pharma Ltd.
The deployment of automated packaging lines and the implementation of software robots at UroGen Pharma Ltd. (URGN) directly impact operational efficiency. The EBITDA financial metric on GURU.Markets measures net cash flow from core operations, excluding the impact of taxes, depreciation, and borrowing costs. The current value of 0.00 reflects the business's actual ability to generate cash amid the Fed's tight monetary policy. The trend of this metric allows for an assessment of the company's speed of adaptation to high borrowing costs, which determines the fundamental stability of the issuer's market value.
Who UroGen Pharma Ltd. competes with
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|BCAX (Bicara Bio) - Operating profit EBITDA|Profit before interest, taxes and amortization Personalis Genomics PSNL|Operating profit before deduction of amortization ERAS (Erasca, Inc.)|Operating profit EBITDA delcath.com (DCTH)|Profit before payment of interest, taxes and amortization Y-mAbs Therapeutics, Inc. YMAB|Income before deduction of interest, taxes and amortization AURA|CADL - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Accuray, Inc.|SLS: Operating profit EBITDA|Operating profit before depreciation charges actuatetherapeutics.com ACTU|CTOR (Citius Oncology) - Operating profit EBITDA|Profit before interest, taxes and amortization TuHURA HURA|Profit before payment of interest, taxes and amortization Protara (TARA)|Fate Pharma - Operating profit before amortization|Aadi Bioscience - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TCRX|CSBR - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization XBIT|CVM: Operating profit EBITDA|OS Therapies, Inc. - Income before deduction of interest, taxes and amortization|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Operating profit EBITDA Artiva|Profit before payment of interest, taxes and amortization Adlai Nortye Ltd. (ANL)|VERU (Veru Inc) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Tx TPST|XLO - Operating profit before deduction of amortization|Enochian BioSciences - Operating profit EBITDA|MURA - Operating profit EBITDA|KAPA (kairospharma.com) - Operating profit before deduction of amortization|OnKure Therapeutics - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization CytoMed Therapeutics Ltd|Profit before payment of interest, taxes and amortization CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (Advanced Biomed)|GNPX: Operating profit before amortization|CLDI: Operating profit before deduction of amortization|Operating income before deduction of amortization sunshinebiopharma.com SBFM|XBIO (xeneticbio.com) - Operating profit before deduction of amortization|salariuspharma.com (SLRX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AONC: Income before deduction of interest, taxes and amortization|Operating profit EBITDA BGNE|Checkpoint Therapeutics Inc (CKPT) - Operating profit before depreciation charges|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD: Operating profit before amortization|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX: Operating profit EBITDA|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|Operating profit before amortization AAPGV (ascentage.com)
